Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 206 resultados
LastUpdate Última actualización 12/10/2025 [06:51:00]
pdfxls
Solicitudes publicadas en los últimos 15 días / Applications published in the last 15 days
previousPage Resultados 50 a 75 de 206 nextPage  

PRESSURIZED NANOEMULSION

NºPublicación:  AU2024243121A1 09/10/2025
Solicitante: 
BIOFRONTERA BIOSCIENCE GMBH
BIOFRONTERA BIOSCIENCE GMBH
AU_2024243121_PA

Resumen de: AU2024243121A1

The present invention relates to stabilizing an oil in water nanoemulsion in a pressurized container. The nanovesicles comprised in the nanoemulsion are particularly stable in regard to vesicle size and vesicle size homogeneity after long-term storage at different temperatures.

NANOEMULSION WITHOUT PROPYLENE GLYCOL

NºPublicación:  AU2024253808A1 09/10/2025
Solicitante: 
BIOFRONTERA BIOSCIENCE GMBH
BIOFRONTERA BIOSCIENCE GMBH
AU_2024253808_PA

Resumen de: AU2024253808A1

The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.

METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY

NºPublicación:  AU2024252371A1 09/10/2025
Solicitante: 
ROCK BIOMEDICAL INC
ROCK BIOMEDICAL INC
AU_2024252371_PA

Resumen de: AU2024252371A1

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g.. a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

NANO-PARTICLES OF MENAQUINONE-9 AND METHODS OF TREATMENT

NºPublicación:  AU2024225887A1 09/10/2025
Solicitante: 
EPIZON INC
EPIZON, INC
AU_2024225887_A1

Resumen de: AU2024225887A1

The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.

DELIVERY OF GENE EDITING SYSTEMS AND METHODS OF USE THEREOF

NºPublicación:  AU2024236558A1 09/10/2025
Solicitante: 
RENAGADE THERAPEUTICS MAN INC
RENAGADE THERAPEUTICS MANAGEMENT INC
AU_2024236558_A1

Resumen de: AU2024236558A1

The present disclosure describes improved LNP-based nucleobase editing systems and therapeutics for use in treating a disease. In particular, the disclosure describes improved LNPs, including novel and improved ionic lipids for making LNPs, that enhance the targeted delivery of LNP-based nucleobase editing systems and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced nucleobase editing systems and/or therapeutic agents.

NOVEL STRUCTURAL LIPIDS FOR LIPID NANOPARTICLE FORMULATION

NºPublicación:  AU2024226024A1 09/10/2025
Solicitante: 
RIBOPRO B V
RIBOPRO B.V
AU_2024226024_A1

Resumen de: MX2025009878A

<p num="0000"/>

IVT MESSENGER RNA AND METHODS OF TREATING OR PREVENTING PFIC TYPE IV

NºPublicación:  WO2025212858A1 09/10/2025
Solicitante: 
CHILDRENS HOSPITAL MEDICAL CENTER [US]
CHILDREN'S HOSPITAL MEDICAL CENTER

Resumen de: WO2025212858A1

Disclosed are in vitro transcribed (IVT) messenger RNAs (mRNAs) comprising a polynucleotide that encodes human TJP2 gene, a 5' terminal cap, and a poly-adenylation (poly- A) tail at the 3' terminal end. In aspects, the polynucleotide is substantially free of uridine bases and comprises pseudouridine bases. Methods, compositions and uses employing the IVT mRNA for treating or preventing progressive familial intrahepatic Cholestasis type IV (PFIC type 4) in a patient in need thereof is also disclosed.

METHODS OF SYNTHESIZING AMINE LIPIDS

NºPublicación:  WO2025212932A1 09/10/2025
Solicitante: 
INTELLIA THERAPEUTICS INC [US]
INTELLIA THERAPEUTICS, INC

Resumen de: WO2025212932A1

Described herein are methods of synthesizing ionizable amine lipids, such as Lipid A: Formula (I) with increased overall purity, process robustness and an applied impurity control strategy, leading to a substantially pure Lipid A product. Intermediate compounds and methods of synthesizing intermediate compounds are also described.

NANOPARTICLE MANUFACTURING

NºPublicación:  WO2025212530A1 09/10/2025
Solicitante: 
N FOLD LLC [US]
N-FOLD LLC

Resumen de: WO2025212530A1

The present disclosure provides nanoparticle compositions in which individual nanoparticles comprise payloads, as well as methods of making and using such nanoparticle compositions, and various compositions and/or technologies relating to such nanoparticle compositions, their production, and/or their use.

LIPID NANOPARTICLES FOR STIMULATING T CELLS

NºPublicación:  WO2025210521A1 09/10/2025
Solicitante: 
GENEVANT SCIENCES GMBH [CH]
GENEVANT SCIENCES GMBH

Resumen de: WO2025210521A1

The present disclosure provides lipid nanoparticles that are particularly beneficial in inducing an immune response in a subject, particularly by stimulating CD8+ T cells associated with protein or protein fragments of interest. The lipid nanoparticles can have a negative zeta potential and/or particular configurations and/or relative amounts of a phospholipid, an ionizable lipid, and a conjugated lipid. The disclosure also provides vaccines, other pharmaceutical compositions, and methods including the provided lipid nanoparticles.

ENPP1 GENE THERAPY FOR THE TREATMENT OF VASCULAR DISEASE

NºPublicación:  WO2025213139A1 09/10/2025
Solicitante: 
THE GENERAL HOSPITAL CORP [US]
THE BRIGHAM AND WOMENS HOSPITAL INC [US]
THE GENERAL HOSPITAL CORPORATION,
THE BRIGHAM AND WOMEN'S HOSPITAL, INC
US_2025312482_PA

Resumen de: WO2025213139A1

Provided herein are compositions and methods for gene therapy for disorders of arterial calcification as well as Generalized Arterial Calcification of Infancy (GACI). The methods include a gene addition strategy to deliver a DNA construct to target tissues (such as liver and smooth muscle cells) to express soluble recombinant ENPP1 (srENPP1) or transmembrane full-length recombinant ENPP1 (rENPP1).

GOLD NANOZYME COMPRISING GLYCOL CHITOSAN AND GOLD PARTICLES, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE COMPRISING SAME

NºPublicación:  EP4628070A1 08/10/2025
Solicitante: 
IUCF HYU [KR]
IUCF-HYU (Industry-University Cooperation Foundation Hanyang University)
EP_4628070_A1

Resumen de: EP4628070A1

One aspect according to the present invention relates to: a gold nanozyme including glycol chitosan and gold particles; and a pharmaceutical composition for preventing or treating inflammatory bowel disease, the composition comprising the gold nanozyme. The gold nanozyme and the pharmaceutical composition comprising same according to one aspect of the present invention was found to inhibit the expression of inflammatory factors, inhibit the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) inside cells, and reduce the production of nitric oxide (NO) inside cells. In addition, the gold nanozyme was found to inhibit the secretion of Hight Mobility Group Box 1 (HMGB1) when further including glycyrrhizin. In addition, the gold nanozyme and the composition comprising same were found to enable the recovery of the length, weight, etc., of damaged intestines, and thus can be used in the inflammatory bowel disease prevention and/or treatment industry/market.

LONG NON-CODING RNA LIPTER PRESERVES LIPID METABOLISM OF THE HUMAN HEART

NºPublicación:  EP4627085A1 08/10/2025
Solicitante: 
UNIV INDIANA TRUSTEES [US]
The Trustees of Indiana University
WO_2024118378_PA

Resumen de: WO2024118378A1

Compositions and methods are disclosed for treating metabolic syndrome-associated heart disease cardiomyopathy and/or heart failure, wherein the method comprises the step of increasing the concentration of LIPTER RNA in the cardiomyocytes of said patient.

LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS AND LIPID-ANCHORED POLYMERS

NºPublicación:  EP4626402A1 08/10/2025
Solicitante: 
GENERATION BIO CO [US]
Generation Bio Co
WO_2024119103_A1

Resumen de: WO2024119103A1

Provided herein are lipid nanoparticles (LNPs) comprising a therapeutic nucleic acid (TNA) and uses thereof. The LNPs comprise an ionizable lipid; a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, and do not comprise a helper lipid.

NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME

NºPublicación:  EP4626400A1 08/10/2025
Solicitante: 
GENERATION BIO CO [US]
Generation Bio Co
KR_20250131271_PA

Resumen de: AU2023406321A1

The present disclosure provides novel polymer-conjugated lipids, e.g., comprising DODA conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations.

LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS, IONIZABLE LIPIDS, STEROLS, LIPID ANCHORED POLYMERS AND HELPER LIPIDS, THEIR USES

NºPublicación:  EP4626444A2 08/10/2025
Solicitante: 
GENERATION BIO CO [US]
Generation Bio Co
CN_120641085_A

Resumen de: AU2023406303A1

Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA), wherein the LNP comprises an ionizable lipid; a "helper" lipid, e.g., a ceramide or distearoylphosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, as well as uses thereof.

STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

NºPublicación:  EP4626401A1 08/10/2025
Solicitante: 
GENERATION BIO CO [US]
Generation Bio Co
CN_120615013_A

Resumen de: AU2023406483A1

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types,

LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND FORMULATIONS

NºPublicación:  EP4626859A1 08/10/2025
Solicitante: 
PRIME MEDICINE INC [US]
Prime Medicine, Inc
WO_2024119098_PA

Resumen de: WO2024119098A1

The present disclosure describes compositions, nanoparticles (such as lipid nanoparticles), and/or lipid nanoparticle compositions and methods of their use.

BISPECIFIC ANTIBODIES AGAINST CANINE CD3 AND CD20

NºPublicación:  EP4626467A1 08/10/2025
Solicitante: 
PETMEDIX LTD [GB]
Petmedix Ltd
MX_2025006274_A

Resumen de: MX2025006274A

This disclosure provides a bispecific canine antigen-binding molecule comprising a first antigen binding domain or antigen-binding portion thereof that specifically binds canine CD3, and a second antigen binding domain or antigen-binding portion thereof that specifically binds canine CD20, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD3, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD20, compositions comprising the same, and methods of their use.

SURFACE MODIFIED CARBON NANOTUBES AND USES THEREOF

NºPublicación:  EP4626483A1 08/10/2025
Solicitante: 
LUNA LABS USA LLC [US]
Luna Labs USA, LLC
AU_2023401698_PA

Resumen de: AU2023401698A1

Provided herein are pharmaceutical compositions comprising surface functionalized carbon nanotube and an active agent. The active agent can be attached to the carbon nanotube covalently or noncovalently. Also provided are methods of preparing the pharmaceutical compositions and methods of use thereof.

STABLE TOPICAL NANOEMULSION COMPRISING MEGLUMINE ANTIMONIATE AND AMPHOTERICIN B FOR THE TREATMENT OF CUTANEOUS LEISHMANIASIS

NºPublicación:  EP4628102A2 08/10/2025
Solicitante: 
FUNDACAO OSWALDO CRUZ [BR]
Funda\u00E7\u00E3o Oswaldo Cruz
EP_4628102_PA

Resumen de: EP4628102A2

The drugs available for the treatment of cutaneous leishmaniasis have unsatisfactory efficacy, frequent and serious adverse effects, and require long treatment regimens. Thus, the search for new treatment alternatives for cutaneous leishmaniasis is considered a priority by the World Health Organization. Parenteral administration of pentavalent antimonials for the treatment of all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. The therapy is long, requires repeated doses, and adverse reactions are frequent. Topical treatment is an attractive alternative for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer adverse effects, ease of administration, and lower costs. The present inventors aimed to provide a fixed-dose topical composition containing at least one antileishmanial compound, providing adequate absorption of the active ingredient. Another objective of the present invention is to provide a topical, fixed-dose formulation containing a combination of antileishmanial compounds that has sufficient efficacy and safety to be used in the treatment of cutaneous leishmaniasis.

STEROID-CATIONIC LIPID COMPOUND AND USE THEREOF

NºPublicación:  EP4628496A1 08/10/2025
Solicitante: 
JENKEM TECH CO LTD LIAONING [CN]
CANSINO SHANGHAI BIOLOGICAL RES CO LTD [CN]
Jenkem Technology Co., Ltd. (Liaoning),
Cansino (Shanghai) Biological Research Co., Ltd
EP_4628496_A1

Resumen de: EP4628496A1

A steroid-cationic lipid compound as represented by formula (I). The LNP prepared from the compound can deliver a bioactive substance to a target cell or organ in an effective and stable manner, and the mRNA LNP prepared from the compound has good levels of stability and transfection efficiency, and can trigger a relatively high specific antibody response and cellular immune response in an animal.

PHOSPHATIDYLAMINE COMPOUND COMPRISING MULTIPLE TERTIARY AMINO GROUP STRUCTURES, AND COMPOSITION AND USE THEREOF

NºPublicación:  EP4628494A1 08/10/2025
Solicitante: 
UNIV BEIJING [CN]
PROXYBIO THERAPEUTICS SHENZHEN CO LTD [CN]
Peking University,
Proxybio Therapeutics (Shenzhen) Co., Ltd
EP_4628494_A1

Resumen de: EP4628494A1

A phosphatidylamine compound including a plurality of tertiary amino group structures and the composition and use thereof are provided. The phosphatidylamine compound is a phospholipid compound including two or more tertiary amino group structures, the structure of which is represented by the following formula (I), where, the definition of each substituent is detailed in the instructions. The compound works together with other lipid components such as cholesterol, DSPC/DOPE, DMG-PEG2000, and other helper lipids to form lipid nanoparticles (LNPs), which may be used for efficient delivery of drug molecules such as nucleic acids (siRNA, mRNA, pDNA), thereby realizing diagnosis and treatment of diseases such as cancer, fibrosis (e.g., liver, lung, kidney).

SYNTHETIC SINGLE-STRANDED DNA MOLECULES AND METHODS OF PRODUCING AND USING THE SAME

NºPublicación:  EP4626475A1 08/10/2025
Solicitante: 
GENERATION BIO CO [US]
Generation Bio Co
KR_20250131270_PA

Resumen de: AU2023406947A1

The present application discloses modified single-stranded DNA molecules, as well as their cell-free methods of synthesis and their use as therapeutic agents.

NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME

Nº publicación: EP4626858A1 08/10/2025

Solicitante:

UNIV CINCINNATI [US]
University of Cincinnati

WO_2024119037_PA

Resumen de: WO2024119037A1

Provided herein are an ionizable lipid compound, a lipid nanoparticle comprising the ionizable lipid compound, a composition comprising an mRNA formulated in the lipid nanoparticle, and a method of delivering an mRNA to a subject or a cell by administering the composition including an mRNA formulated in the lipid nanoparticle to the subject or cell.

traducir